Business
Aclarion Provides 2025 Update and 2026 Corporate Outlook
Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growthCompany aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026 BROOMFIELD, Colo., Jan.
About this update from Aclarion, Inc.
[{"type":"image","alt":"Aclarion, Inc.","displaySize":"","headline":null,"caption":"Aclarion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JqjNbxSKpdl2ksI_nXtiLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ba6de721dd8ef6e3bce232e051476ebf","width":140,"height":83}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Annual Nociscan scan volumes increased 69% year-over-year in 2025","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growth","length":175,"tagName":"p"}]},{"val":[{"type":"text","content":"Company aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026","length":163,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":475,"olType":false},{"type":"text","content":"BROOMFIELD, Colo., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain today provided a comprehensive corporate update, including financial results and strategic progress as the Company enters 2026 advancing its proprietary Nociscan platform.","length":493,"tagName":"p"},{"type":"text","content":"Market Adoption & Growth Momentum","length":37,"tagName":"p"},{"type":"text","content":"During 2025, Aclarion continued to build on its mission to transform the diagnosis of chronic low back pain achieving 69% year-over-year scan volume growth.","length":156,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Nociscan scan volumes increased +114% year-over-year in Q4 2025 – marking the third consecutive quarter of year-over-year growth across U.S.,...